231277-92-2 | N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine

Packsize	Purity	Availability	Price	Discounted Price
50mg	95%	in stock	$22.00	$15.00
100mg	95%	in stock	$30.00	$21.00
250mg	95%	in stock	$38.00	$26.00
1g	95%	in stock	$87.00	$61.00
5g	95%	in stock	$249.00	$175.00
10g	95%	in stock	$401.00	$281.00
25g	95%	in stock	$758.00	$531.00

Description

• Catalog Number: AB52181
• Chemical Name: N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine
• CAS Number: 231277-92-2
• Molecular Formula: C29H26ClFN4O4S
• Molecular Weight: 581.0575
• MDL Number: MFCD09264194
• SMILES: Fc1cccc(c1)COc1ccc(cc1Cl)Nc1ncnc2c1cc(cc2)c1ccc(o1)CNCCS(=O)(=O)C
• NSC Number: 745750

Computed Properties

• Complexity: 898
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 40
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 11
• XLogP3: 5.1

Literature

• Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes.

  Toxicology letters 20180701

• The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation.

  The Journal of biological chemistry 20170908

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• P450 3A-Catalyzed O-Dealkylation of Lapatinib Induces Mitochondrial Stress and Activates Nrf2.

  Chemical research in toxicology 20160516

• Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.

  The international journal of biochemistry & cell biology 20160201

• Better Together: Targeted Combination Therapies in Breast Cancer.

  Seminars in oncology 20151201

• Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.

  Toxicology and applied pharmacology 20150815

• Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.

  Journal of medicinal chemistry 20141009

• CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.

  Genes & cancer 20140701

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer.

  European journal of medicinal chemistry 20131101

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Lapatinib inhibits meiotic maturation of porcine oocyte-cumulus complexes cultured in vitro in gonadotropin-supplemented medium.

  Fertility and sterility 20130501

• Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20130501

• A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.

  The Biochemical journal 20130415

• Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.

  Investigational new drugs 20121201

• New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).

  Medical oncology (Northwood, London, England) 20121201

• Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.

  Oncology reports 20121201

• Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.

  Molecular pharmaceutics 20121105

• Behavior and anti-glioma effect of lapatinib-incorporated lipoprotein-like nanoparticles.

  Nanotechnology 20121102

• Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going?

  Critical reviews in oncology/hematology 20121101

• Dual blockade of HER2 - twice as good or twice as toxic?

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20121101

• Targeted therapy in brain metastasis.

  Current opinion in oncology 20121101

• The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.

  Glia 20121101

• Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.

  Toxicological sciences : an official journal of the Society of Toxicology 20121101

• Lapatinib and renal cell carcinoma.

  Expert opinion on investigational drugs 20121101

• Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.

  Gynecologic oncology 20121101

• Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.

  The European journal of health economics : HEPAC : health economics in prevention and care 20121001

• A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.

  Investigational new drugs 20121001

• Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.

  Molecular bioSystems 20121001

• Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.

  Molecular oncology 20121001

• Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.

  Breast cancer research and treatment 20121001

• Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.

  British journal of cancer 20120925

• A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120910

• BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.

  British journal of cancer 20120904

• Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial.

  British journal of cancer 20120904

• Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling.

  Medical oncology (Northwood, London, England) 20120901

• Targeted therapy for gastric cancer.

  Current treatment options in oncology 20120901

• T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.

  The Journal of investigative dermatology 20120901

• Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

  Molecular cancer therapeutics 20120901

• Recent advances in novel targeted therapies for HER2-positive breast cancer.

  Anti-cancer drugs 20120901

• Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.

  Neuro-oncology 20120901

• The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies.

  Therapeutic advances in medical oncology 20120901

• Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120901

• Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.

  Anticancer research 20120901

• Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma.

  Expert review of anticancer therapy 20120901

• A functional comparison between the HER2(high)/HER3 and the HER2(low)/HER3 dimers on heregulin-β1-induced MMP-1 and MMP-9 expression in breast cancer cells.

  Experimental & molecular medicine 20120831

• Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.

  Fundamental & clinical pharmacology 20120801

• Docetaxel combined with targeted therapies in metastatic breast cancer.

  Cancer treatment reviews 20120801

• Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer.

  Nanomedicine : nanotechnology, biology, and medicine 20120801

• New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

  Cancer treatment reviews 20120801

• Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study.

  Molecular oncology 20120801

• Trigeminal nerve injury ErbB3/ErbB2 promotes mechanical hypersensitivity.

  Anesthesiology 20120801

• Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).

  Current medical research and opinion 20120801

• Combined effects of lapatinib and cisplatin on colony formation of head and neck squamous cell carcinoma.

  Anticancer research 20120801

• Lapatinib or trastuzumab in combination with an aromatase inhibitor for first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2.

  The Lancet. Oncology 20120801

• Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

  Expert review of anticancer therapy 20120801

• Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

  Nature 20120726

• Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120720

• Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.

  Oncogene 20120719

• CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set.

  Cancer research 20120715

• Clinical studies in the second line setting of advanced pancreatic cancer: are we making any progress?

  JOP : Journal of the pancreas 20120710

• Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?

  Breast cancer (Tokyo, Japan) 20120701

• Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.

  International journal of cancer 20120701

• Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer.

  The Prostate 20120701

• A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer.

  Breast cancer research and treatment 20120701

• Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.

  British journal of pharmacology 20120701

• Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.

  Breast cancer research and treatment 20120701

• Interaction of lapatinib with cytochrome P450 3A5.

  Drug metabolism and disposition: the biological fate of chemicals 20120701

• ErbB3 inhibitory surrobodies inhibit tumor cell proliferation in vitro and in vivo.

  Molecular cancer therapeutics 20120701

• The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).

  International journal of oncology 20120701

• Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

  Breast cancer research and treatment 20120701

• Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.

  Breast cancer research and treatment 20120701

• [A case of HER2-positive breast cancer receiving lapatinib+capecitabine chemotherapy with ventriculoperitoneal shunting for hydrocephalus associated with brain metastases].

  Gan to kagaku ryoho. Cancer & chemotherapy 20120701

• Concurrent HER2 vaccination and inhibition of kinase activity: safety and immunogenicity.

  Immunotherapy 20120701

• New insights and emerging therapies for breast cancer brain metastases.

  Oncology (Williston Park, N.Y.) 20120701

• Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.

  Drugs 20120618

• Current and emerging targeted therapies for metastatic breast cancer.

  Cancer 20120615

• GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance.

  Biochemical pharmacology 20120615

• Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening.

  Bioorganic & medicinal chemistry letters 20120615

• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  Journal of medicinal chemistry 20120614

• HER2 testing in patients with breast cancer.

  BMJ (Clinical research ed.) 20120611

• Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.

  Breast cancer research and treatment 20120601

• The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120601

• Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence.

  Breast cancer research and treatment 20120601

• The adjuvant treatment of HER2-positive breast cancer.

  Current treatment options in oncology 20120601

• Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.

  Oncology reports 20120601

• Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120601

• An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry.

  Analytical and bioanalytical chemistry 20120601

• The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer.

  Clinical breast cancer 20120601

• [Tumor resistance to HER2 inhibitors: the drug sedimentation concept].

  Bulletin du cancer 20120601

• A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study.

  Journal of gastrointestinal oncology 20120601

• Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

  International journal of cancer 20120515

• HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.

  Cancer research 20120515

• Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma.

  Talanta 20120515

• Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.

  Cell 20120511

• Genetic heterogeneity in HER2 testing may influence therapy eligibility.

  Breast cancer research and treatment 20120501

• Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer.

  Cancer chemotherapy and pharmacology 20120501

• Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.

  Oncology reports 20120501

• Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.

  Molecular pharmacology 20120501

• Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

  Cancer discovery 20120501

• Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition.

  Neoplasia (New York, N.Y.) 20120501

• A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120415

• FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer.

  Oncogene 20120405

• Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

  Investigational new drugs 20120401

• Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells.

  Investigational new drugs 20120401

• Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.

  Breast cancer research and treatment 20120401

• HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer.

  Cancer treatment reviews 20120401

• Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.

  Journal of cellular physiology 20120401

• Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120401

• How informative is a negative finding in a small pharmacogenetic study?

  The pharmacogenomics journal 20120401

• Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

  Gastroenterology 20120401

• Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

  Breast cancer research and treatment 20120401

• Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.

  Molecular pharmacology 20120401

• Insight into p95HER2 in breast cancer: molecular mechanisms and targeted therapies.

  Recent patents on DNA & gene sequences 20120401

• Expression of matrix metalloproteinase-7 is an unfavorable prognostic factor in intrahepatic cholangiocarcinoma.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20120401

• Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

  Molecular cancer therapeutics 20120401

• Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes.

  Clinical pharmacology and therapeutics 20120401

• HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.

  Molecular cancer therapeutics 20120401

• Lapatinib for advanced or metastatic breast cancer.

  The oncologist 20120401

• [Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].

  Zhongguo shi yan xue ye xue za zhi 20120401

• Improving treatment of HER2-positive cancers: opportunities and challenges.

  Science translational medicine 20120328

• A water-based mechanism of specificity and resistance for lapatinib with ErbB family kinases.

  Biochemistry 20120327

• Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.

  Journal of medicinal chemistry 20120322

• Sensitivity control through attenuation of signal transfer efficiency by negative regulation of cellular signalling.

  Nature communications 20120313

• Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

  Pharmaceutical research 20120301

• A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study.

  Gynecologic oncology 20120301

• Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting.

  Acta neuropathologica 20120301

• [Renal tolerance of targeted therapies].

  Bulletin du cancer 20120301

• MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

  Molecular cancer therapeutics 20120301

• Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

  Molecular cancer therapeutics 20120301

• Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?

  The oncologist 20120301

• Metabolism of phosphatidylinositol 4-kinase IIIα-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity.

  PLoS pathogens 20120301

• Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

  Oncotarget 20120301

• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  Lancet (London, England) 20120218

• Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2.

  British journal of cancer 20120214

• Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.

  Journal of cellular physiology 20120201

• ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells.

  Breast cancer research and treatment 20120201

• Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

  Clinical breast cancer 20120201

• Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.

  Cellular signalling 20120201

• The role of lapatinib in the preoperative therapy of breast cancer.

  Current oncology reports 20120201

• Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.

  Anti-cancer agents in medicinal chemistry 20120201

• Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.

  Cancer science 20120201

• Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.

  Molecular & cellular proteomics : MCP 20120201

• Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.

  Breast cancer research and treatment 20120201

• Treatment of vestibular schwannoma cells with ErbB inhibitors.

  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 20120201

• Don't pick the loser: lessons from the GeparQuinto trial.

  The Lancet. Oncology 20120201

• Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

  The Lancet. Oncology 20120201

• Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.

  Future oncology (London, England) 20120201

• Advances in medical therapies for Cushing's syndrome.

  Discovery medicine 20120201

• In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

  Neoplasia (New York, N.Y.) 20120201

• Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma.

  Clinica chimica acta; international journal of clinical chemistry 20120118

• Synthesis and biological evaluation of 4-[3-chloro-4-(3-fluorobenzyloxy)anilino]-6-(3-substituted-phenoxy)pyrimidines as dual EGFR/ErbB-2 kinase inhibitors.

  Bioorganic & medicinal chemistry 20120115

• Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

  British journal of cancer 20120103

• Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.

  British journal of cancer 20120103

• Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20120101

• Targeting the tumor microenvironment: focus on angiogenesis.

  Journal of oncology 20120101

• The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

  Breast cancer research and treatment 20120101

• The Role of PTEN in Tumor Angiogenesis.

  Journal of oncology 20120101

• Dual HER2-targeted approaches in HER2-positive breast cancer.

  Breast cancer research and treatment 20120101

• Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity.

  Drug metabolism and disposition: the biological fate of chemicals 20120101

• Hepatotoxicity associated with lapatinib in an experimental rat model.

  European journal of cancer (Oxford, England : 1990) 20120101

• Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones.

  Bioorganic & medicinal chemistry 20120101

• Exploration of chemical space based on 4-anilinoquinazoline.

  Current medicinal chemistry 20120101

• Ovarian cancer: opportunity for targeted therapy.

  Journal of oncology 20120101

• Role of chemotherapy on brain metastasis.

  Progress in neurological surgery 20120101

• Optical imaging of metabolism in HER2 overexpressing breast cancer cells.

  Biomedical optics express 20120101

• Monoclonal antibodies and Fc fragments for treating solid tumors.

  Biologics : targets & therapy 20120101

• Metabolic syndrome and triple-negative breast cancer: a new paradigm.

  International journal of breast cancer 20120101

• Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].

  Journal of translational medicine 20120101

• Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.

  World journal of surgical oncology 20120101

• Defective cell cycle checkpoints as targets for anti-cancer therapies.

  Frontiers in pharmacology 20120101

• Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

  PloS one 20120101

• Therapy for metastatic melanoma: the past, present, and future.

  BMC medicine 20120101

• What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?

  Oncology (Williston Park, N.Y.) 20120101

• Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.

  Substance abuse treatment, prevention, and policy 20120101

• HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.

  Oncology 20120101

• Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.

  BMC medicine 20120101

• Efficacy and tolerability of lapatinib in the management of breast cancer.

  Breast cancer : basic and clinical research 20120101

• Kindlins, integrin activation and the regulation of talin recruitment to αIIbβ3.

  PloS one 20120101

• SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation.

  BMC surgery 20120101

• Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.

  Critical reviews in oncogenesis 20120101

• Akt: a double-edged sword in cell proliferation and genome stability.

  Journal of oncology 20120101

• Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies.

  Biochemistry research international 20120101

• Target points in trastuzumab resistance.

  International journal of breast cancer 20120101

• Computational identification and modeling of crosstalk between phosphorylation, O-β-glycosylation and methylation of FoxO3 and implications for cancer therapeutics.

  International journal of molecular sciences 20120101

• Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.

  Tumori 20120101

• High lapatinib plasma levels in breast cancer patients: risk or benefit?

  Tumori 20120101

• Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

  Journal of Cancer 20120101

• Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations.

  Clinical Medicine Insights. Oncology 20120101

• Novel therapies in glioblastoma.

  Neurology research international 20120101

• Lestaurtinib inhibits histone phosphorylation and androgen-dependent gene expression in prostate cancer cells.

  PloS one 20120101

• Trastuzumab and Gemcitabine in Pretreated HER2 Overexpressing Metastatic Breast Cancer Patients: Retrospective Analysis of Our Series.

  Journal of oncology 20120101

• Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer.

  Journal of oncology 20120101

• The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer.

  Clinical Medicine Insights. Oncology 20120101

• Integrin signaling in cancer cell survival and chemoresistance.

  Chemotherapy research and practice 20120101

• The molecular biology of vestibular schwannomas and its association with hearing loss: a review.

  Genetics research international 20120101

• Genetics and the potential for predictive tests in adverse drug reactions.

  Chemical immunology and allergy 20120101

• Development and validation of an automated high-throughput system for zebrafish in vivo screenings.

  PloS one 20120101

• Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.

  PloS one 20120101

• Combination drug delivery approaches in metastatic breast cancer.

  Journal of drug delivery 20120101

• Die and let live: harnessing BikDD to combat breast cancer stem cells.

  Breast cancer research : BCR 20120101

• Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment.

  OncoTargets and therapy 20120101

• Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype.

  PloS one 20120101

• Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.

  International journal of breast cancer 20120101

• Targeting the Immune System to Fight Cancer Using Chemical Receptor Homing Vectors Carrying Polyinosine/Cytosine (PolyIC).

  Frontiers in oncology 20120101

• Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity.

  International journal of nanomedicine 20120101

• Deep Sequence Analysis of Non-Small Cell Lung Cancer: Integrated Analysis of Gene Expression, Alternative Splicing, and Single Nucleotide Variations in Lung Adenocarcinomas with and without Oncogenic KRAS Mutations.

  Frontiers in oncology 20120101

• Prostate cancer - a biomarker perspective.

  Frontiers in endocrinology 20120101

• Emerging targeted therapies for castration-resistant prostate cancer.

  Frontiers in endocrinology 20120101

• Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial.

  ISRN oncology 20120101

• [Will targeted therapies replace chemotherapy?].

  Revue medicale de Liege 20120101

• Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis.

  Journal of oncology 20120101

• EGFR inhibition in glioma cells modulates Rho signaling to inhibit cell motility and invasion and cooperates with temozolomide to reduce cell growth.

  PloS one 20120101

• Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.

  Molecular cancer 20120101

• Targeted therapies in breast cancer: are heart and vessels also being targeted?

  Breast cancer research : BCR 20120101

• Concomitant targeting of EGF receptor, TGF-beta and SRC points to a novel therapeutic approach in pancreatic cancer.

  PloS one 20120101

• Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).

  Oncology 20120101

• Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.

  PloS one 20120101

• Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.

  BMC cancer 20120101

• Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.

  PloS one 20120101

• The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.

  Molecular systems biology 20120101

• Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms?

  Cardiology 20120101

• Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.

  PloS one 20120101

• Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.

  PloS one 20120101

• Targeting the HER2 receptor in metastatic breast cancer.

  Hematology/oncology and stem cell therapy 20120101

• hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111215

• Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.

  Journal of medicinal chemistry 20111208

• Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.

  Molecular pharmaceutics 20111205

• Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.

  Investigational new drugs 20111201

• Modulation of P-gp expression by lapatinib.

  Investigational new drugs 20111201

• Current technologies for HER2 testing in breast cancer.

  Critical reviews in oncology/hematology 20111201

• Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.

  International journal of clinical oncology 20111201

• Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives.

  Critical reviews in oncology/hematology 20111201

• Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20111201

• Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.

  Cancer chemotherapy and pharmacology 20111201

• Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.

  Journal of neuro-oncology 20111201

• Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer.

  Molecular & cellular proteomics : MCP 20111201

• Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.

  Current medical research and opinion 20111201

• An overview of letrozole in postmenopausal women with hormone-responsive breast cancer.

  Advances in therapy 20111201

• Mechanistic insights into the activation of oncogenic forms of EGF receptor.

  Nature structural & molecular biology 20111201

• Geminin overexpression induces mammary tumors via suppressing cytokinesis.

  Oncotarget 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Metformin: multi-faceted protection against cancer.

  Oncotarget 20111201

• Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

  Oncotarget 20111201

• Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer.

  Journal of breast cancer 20111201

• Select interviews from the 2011 San Antonio Breast Cancer Symposium (SABCS) and American Society of Hematology (ASH) Annual Meeting.

  Oncology (Williston Park, N.Y.) 20111201

• Treatment of HER2-positive breast cancer: current status and future perspectives.

  Nature reviews. Clinical oncology 20111129

• Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines.

  International journal of cancer 20111115

• Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells.

  British journal of cancer 20111108

• An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.

  British journal of cancer 20111108

• HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

  Breast cancer research and treatment 20111101

• Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy.

  Cancer 20111101

• Resveratrol inhibits the epidermal growth factor-induced epithelial mesenchymal transition in MCF-7 cells.

  Cancer letters 20111101

• Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.

  Expert opinion on pharmacotherapy 20111101

• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

  Nature biotechnology 20111101

• The discovery of lapatinib (GW572016).

  Molecular cancer therapeutics 20111101

• Lapatinib: functional genomics study leads to insights into mechanism of action.

  Molecular cancer therapeutics 20111101

• Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.

  Anticancer research 20111101

• The nuclear epidermal growth factor receptor signaling network and its role in cancer.

  Discovery medicine 20111101

• Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.

  Oncotarget 20111101

• [The effect of immune-based therapy with cytotoxic T lymphocyte and molecular targeting therapy for HER2 in esophageal squamous cell carcinoma].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• [A case of breast cancer liver metastases responding to lapatinib and capecitabine therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20111101

• Chemopreventive activity of vitamin E in breast cancer: a focus on γ- and δ-tocopherol.

  Nutrients 20111101

• Comprehensive analysis of kinase inhibitor selectivity.

  Nature biotechnology 20111030

• Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111015

• Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration.

  Biochemical and biophysical research communications 20111014

• Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.

  Oncogene 20111006

• Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.

  Investigational new drugs 20111001

• How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20111001

• Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.

  European journal of cancer (Oxford, England : 1990) 20111001

• Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review.

  Breast (Edinburgh, Scotland) 20111001

• Drug-induced heart failure.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20111001

• Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance.

  Translational oncology 20111001

• Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

  Breast (Edinburgh, Scotland) 20111001

• Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

  Breast (Edinburgh, Scotland) 20111001

• Identification of potent EGFR inhibitors from TCM Database@Taiwan.

  PLoS computational biology 20111001

• Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

  Oncogene 20110929

• Elucidating an uncommon disease: inflammatory breast cancer.

  Journal of the National Cancer Institute 20110921

• An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

  Cancer discovery 20110915

• BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.

  Cancer cell 20110913

• Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.

  British journal of cancer 20110906

• Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.

  Molecular cell 20110902

• The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

  Breast cancer research and treatment 20110901

• Antitumor activity of NRC-AN-019 in a pre-clinical breast cancer model.

  International journal of oncology 20110901

• Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.

  Cancer biology & therapy 20110901

• Efficacy control of therapy using circulating epithelial tumor cells (CETC) as 'liquid biopsy': trastuzumab in HER2/neu-positive breast carcinoma.

  Journal of cancer research and clinical oncology 20110901

• Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20110901

• Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.

  Anticancer research 20110901

• Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors.

  Future cardiology 20110901

• Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.

  British journal of cancer 20110823

• Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

  Cancer cell 20110816

• Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT.

  Archives of gynecology and obstetrics 20110801

• FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy.

  Current drug targets 20110801

• Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.

  Medical hypotheses 20110801

• Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110801

• Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors.

  Molecular cancer therapeutics 20110801

• Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.

  Molecular cancer therapeutics 20110801

• Current targeted therapies in breast cancer: clinical applications in the elderly woman.

  The oncologist 20110801

• Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110801

• Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• Targeting the HER/EGFR/ErbB family to prevent breast cancer.

  Cancer prevention research (Philadelphia, Pa.) 20110801

• Unraveling the complexity of basal-like breast cancer.

  Oncotarget 20110801

• Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110710

• Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib.

  Oncogene 20110707

• Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.

  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110701

• Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer.

  Breast cancer research and treatment 20110701

• Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.

  Gynecologic oncology 20110701

• Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?

  Expert opinion on investigational drugs 20110701

• Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.

  Current opinion in oncology 20110701

• Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies.

  Current cancer drug targets 20110701

• ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas.

  Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 20110701

• Personalized medicine: new genomics, old lessons.

  Human genetics 20110701

• Targeting invadopodia to block breast cancer metastasis.

  Oncotarget 20110701

• Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented?

  Heart failure clinics 20110701

• Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.

  Histopathology 20110701

• Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.

  Bioorganic & medicinal chemistry letters 20110615

• Small tyrosine kinase inhibitors interrupt EGFR signaling by interacting with erbB3 and erbB4 in glioblastoma cell lines.

  Experimental cell research 20110610

• Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation.

  Science translational medicine 20110608

• A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.

  British journal of cancer 20110607

• PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.

  Oncogene 20110602

• Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation.

  Critical reviews in oncology/hematology 20110601

• The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110601

• Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors.

  British journal of clinical pharmacology 20110601

• Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib.

  Drug metabolism and disposition: the biological fate of chemicals 20110601

• Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab.

  Breast cancer research and treatment 20110601

• Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

  European journal of medicinal chemistry 20110601

• Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.

  International journal of oncology 20110601

• ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.

  Cancer research 20110601

• Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.

  Expert opinion on biological therapy 20110601

• A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network.

  Molecular bioSystems 20110601

• Oral complications of targeted cancer therapies: a narrative literature review.

  Oral oncology 20110601

• Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

  Clinical pharmacokinetics 20110601

• Cancer stem cells: perspectives of new therapeutical approaches for breast cancer.

  Frontiers in bioscience (Scholar edition) 20110601

• [Tykerb for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20110601

• Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.

  Clinical advances in hematology & oncology : H&O 20110601

• Review: lapatinib in metastatic colorectal cancer-another strategy for disease control?

  Clinical advances in hematology & oncology : H&O 20110601

• Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes.

  Journal of breast cancer 20110601

• Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience.

  British journal of cancer 20110524

• Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

  British journal of cancer 20110524

• Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer.

  Oncogene 20110519

• Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110515

• The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

  Cancer research 20110515

• Lapatinib-induced hepatitis: a case report.

  World journal of gastroenterology 20110514

• Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.

  Clinica chimica acta; international journal of clinical chemistry 20110512

• Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration.

  British journal of cancer 20110510

• Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications.

  Cancer biology & therapy 20110501

• Lapatinib plus trastuzumab for a patient with heavily pre-treated gastric cancer that progressed after trastuzumab.

  Japanese journal of clinical oncology 20110501

• Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?

  Expert opinion on drug metabolism & toxicology 20110501

• Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.

  Chinese journal of cancer 20110501

• Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110501

• YB-1 drives preneoplastic progression: Insight into opportunities for cancer prevention.

  Oncotarget 20110501

• Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer.

  Drugs of today (Barcelona, Spain : 1998) 20110501

• HER2-targeted therapies: how far we've come--and where we're headed.

  Oncology (Williston Park, N.Y.) 20110430

• ERK/MAPK pathways play critical roles in EGFR ligands-induced MMP1 expression.

  Biochemical and biophysical research communications 20110422

• p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines.

  International journal of cancer 20110415

• The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer.

  British journal of cancer 20110412

• Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.

  Biochemical and biophysical research communications 20110408

• Hints of future progress for HER-2 breast cancer.

  Journal of the National Cancer Institute 20110406

• Targeting the human EGFR family in esophagogastric cancer.

  Nature reviews. Clinical oncology 20110405

• Use of molecular markers for predicting therapy response in cancer patients.

  Cancer treatment reviews 20110401

• Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines.

  Immunologic research 20110401

• Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.

  Breast (Edinburgh, Scotland) 20110401

• A high content screening assay for identifying lysosomotropic compounds.

  Toxicology in vitro : an international journal published in association with BIBRA 20110401

• A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.

  Magma (New York, N.Y.) 20110401

• KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.

  Oncology reports 20110401

• Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.

  The Journal of biological chemistry 20110401

• Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.

  Biochemical and biophysical research communications 20110401

• Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.

  Molecular cancer therapeutics 20110401

• Gerosuppressant metformin: less is more.

  Aging 20110401

• [Leptomeningeal meningitis related to breast cancer overexpressing HER2: is there a place for a more specific treatment?].

  Bulletin du cancer 20110401

• ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.

  PLoS genetics 20110401

• Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma.

  North American journal of medical sciences 20110401

• Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole--of clinical importance?

  British journal of cancer 20110329

• Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110315

• First-line treatment for advanced pancreatic cancer. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011.

  JOP : Journal of the pancreas 20110309

• Pazopanib: Clinical development of a potent anti-angiogenic drug.

  Critical reviews in oncology/hematology 20110301

• Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110301

• Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy.

  American journal of physiology. Heart and circulatory physiology 20110301

• New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110301

• Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

  Molecular cancer therapeutics 20110301

• Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins.

  Molecular cancer therapeutics 20110301

• Targeted therapies for metastatic esophagogastric cancer.

  Current treatment options in oncology 20110301

• Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.

  Cell cycle (Georgetown, Tex.) 20110301

• Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

  Cancer research 20110301

• Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture.

  Oncotarget 20110301

• Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).

  Anticancer research 20110301

• A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.

  Clinical colorectal cancer 20110301

• HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110220

• A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.

  Archives of gynecology and obstetrics 20110201

• Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110201

• Characteristics of triple-negative breast cancer.

  Journal of cancer research and clinical oncology 20110201

• [Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management].

  Presse medicale (Paris, France : 1983) 20110201

• Lapatinib in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer: profile report.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20110201

• The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?

  Expert review of anticancer therapy 20110201

• HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

  Expert review of anticancer therapy 20110201

• Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.

  Current opinion in obstetrics & gynecology 20110201

• [Her2 positive breast cancer: practices].

  Bulletin du cancer 20110201

• The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.

  Clinical breast cancer 20110201

• Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.

  British journal of cancer 20110118

• Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.

  British journal of cancer 20110118

• AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.

  Cancer cell 20110118

• Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.

  Cancer biology & therapy 20110115

• Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110110

• Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.

  Breast cancer (Tokyo, Japan) 20110101

• Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

  Journal of cellular physiology 20110101

• Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.

  Cancer science 20110101

• High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

  Breast cancer research and treatment 20110101

• Lapatinib for breast cancer: a review of the current literature.

  Expert opinion on drug safety 20110101

• HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.

  Molecular endocrinology (Baltimore, Md.) 20110101

• Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.

  Pathology research international 20110101

• Testing for HER2 in Breast Cancer: A Continuing Evolution.

  Pathology research international 20110101

• EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.

  Frontiers in bioscience (Landmark edition) 20110101

• Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.

  BMC cancer 20110101

• Receptor tyrosine kinases as therapeutic targets in rhabdomyosarcoma.

  Sarcoma 20110101

• Blood-brain barrier integrity and breast cancer metastasis to the brain.

  Pathology research international 20110101

• Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101

• Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.

  Current medicinal chemistry 20110101

• HER2-positive circulating tumor cells in breast cancer.

  PloS one 20110101

• Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

  BMC cancer 20110101

• Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)-paclitaxel nanoparticles.

  International journal of nanomedicine 20110101

• Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.

  PloS one 20110101

• Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.

  Molecular cancer 20110101

• Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux® and particle therapy].

  BMC cancer 20110101

• miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis.

  Journal of Cancer 20110101

• Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib.

  Breast cancer research : BCR 20110101

• Functional characterization of human cancer-derived TRKB mutations.

  PloS one 20110101

• Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.

  Breast cancer research : BCR 20110101

• Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.

  PloS one 20110101

• Conceptual aspects of large meta-analyses with publicly available microarray data: a case study in oncology.

  Bioinformatics and biology insights 20110101

• An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development.

  Journal of Cancer 20110101

• A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study.

  Journal of experimental & clinical cancer research : CR 20110101

• A theoretical entropy score as a single value to express inhibitor selectivity.

  BMC bioinformatics 20110101

• Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.

  Breast cancer : basic and clinical research 20110101

• Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.

  Breast cancer research : BCR 20110101

• Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer.

  BMC cancer 20110101

• Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.

  Current topics in medicinal chemistry 20110101

• Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

  Breast cancer research : BCR 20110101

• Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report.

  Case reports in oncology 20110101

• Serum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.

  PloS one 20110101

• Target therapies in lung cancer.

  Journal of biomedicine & biotechnology 20110101

• New developments in the treatment of metastatic gastric cancer: focus on trastuzumab.

  OncoTargets and therapy 20110101

• Novel therapeutic strategies for targeting liver cancer stem cells.

  International journal of biological sciences 20110101

• The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.

  PloS one 20110101

• Critical appraisal of trastuzumab in treatment of advanced stomach cancer.

  Cancer management and research 20110101

• Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies.

  PloS one 20110101

• Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.

  Onkologie 20110101

• Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood.

  Journal of oncology 20110101

• Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore.

  BMC cancer 20110101

• Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.

  Journal of computer assisted tomography 20110101

• [Breast cancer therapy with combination of endocrine and target drugs].

  Voprosy onkologii 20110101

• Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.

  Breast cancer research : BCR 20110101

• Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer.

  Breast cancer : basic and clinical research 20110101

• Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.

  Breast cancer research : BCR 20110101

• PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

  BMC cancer 20110101

• Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality.

  BMC cancer 20110101

• Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.

  PloS one 20110101

• Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.

  Breast cancer research : BCR 20110101

• Very low prevalence of epidermal growth factor receptor (EGFR) protein expression and gene amplification in Saudi breast cancer patients.

  Diagnostic pathology 20110101

• Targeted therapy in breast cancer: what's new?

  Swiss medical weekly 20110101

• Promising molecular targeted therapies in breast cancer.

  Indian journal of pharmacology 20110101

• Immune effects of trastuzumab.

  Journal of Cancer 20110101

• Combined logical and data-driven models for linking signalling pathways to cellular response.

  BMC systems biology 20110101

• Proteomic analysis of pathways involved in estrogen-induced growth and apoptosis of breast cancer cells.

  PloS one 20110101

• Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.

  Breast cancer research : BCR 20110101

• Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.

  Therapeutic advances in medical oncology 20110101

• AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo.

  PloS one 20110101

• Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies.

  Head & neck oncology 20110101

• Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines.

  Breast cancer : basic and clinical research 20110101

• Current therapeutic strategies for invasive and metastatic bladder cancer.

  OncoTargets and therapy 20110101

• Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval.

  OncoTargets and therapy 20110101

• Epidermal growth factor receptor expression in urinary bladder cancer.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• [Targeted therapies in breast cancer].

  Revue medicale de Liege 20110101

• Targeting ErbB receptors in high-grade glioma.

  Current pharmaceutical design 20110101

• Current neoadjuvant treatment options for HER2-positive breast cancer.

  Biologics : targets & therapy 20110101

• Herceptin conjugates linked by EDC boost direct tumor cell death via programmed tumor cell necrosis.

  PloS one 20110101

• Management options in triple-negative breast cancer.

  Breast cancer : basic and clinical research 20110101

• Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.

  BMC cancer 20110101

• β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.

  Breast cancer research : BCR 20110101

• Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

  Breast cancer research : BCR 20110101

• Androgen receptor signaling in prostate cancer development and progression.

  Journal of carcinogenesis 20110101

• Bridging from preclinical to clinical studies for tyrosine kinase inhibitors based on pharmacokinetics/pharmacodynamics and toxicokinetics/toxicodynamics.

  Drug metabolism and pharmacokinetics 20110101

• Chemotherapy in advanced bladder cancer: current status and future.

  Journal of hematology & oncology 20110101

• The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?

  Clinical proteomics 20110101

• Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.

  Breast cancer research : BCR 20110101

• A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death.

  PloS one 20110101

• Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death.

  BMC cancer 20110101

• Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.

  PloS one 20110101

• A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis.

  Breast cancer research : BCR 20110101

• Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.

  OncoTargets and therapy 20110101

• The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

  BMC cancer 20110101

• Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.

  Molecular cancer 20110101

• Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.

  PloS one 20110101

• The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer.

  PloS one 20110101

• Human epidermal growth factor receptor bispecific ligand trap RB200: abrogation of collagen-induced arthritis in combination with tumour necrosis factor blockade.

  Arthritis research & therapy 20110101

• Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

  BMC health services research 20110101

• The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.

  PloS one 20110101

• Lapatinib in the treatment of HER-2 overexpressing breast cancer.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20110101

• The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.

  BMC cancer 20110101

• The important molecular markers on chromosome 17 and their clinical impact in breast cancer.

  International journal of molecular sciences 20110101

• A mechanism for synergy with combined mTOR and PI3 kinase inhibitors.

  PloS one 20110101

• Surrogate markers for targeted therapy-based treatment activity and efficacy.

  Journal of the National Cancer Institute. Monographs 20110101

• Neoadjuvant chemotherapy and targeted therapies: a promising strategy.

  Journal of the National Cancer Institute. Monographs 20110101

• Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.

  Journal of the National Cancer Institute. Monographs 20110101

• Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

  PloS one 20110101

• A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells.

  PloS one 20110101

• A rare bladder cancer--small cell carcinoma: review and update.

  Orphanet journal of rare diseases 20110101

• Protein biomarkers for the early detection of breast cancer.

  International journal of proteomics 20110101

• Metastatic bladder cancer: a review of current management.

  ISRN urology 20110101

• Signatures of drug sensitivity in nonsmall cell lung cancer.

  International journal of proteomics 20110101

• Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.

  ISRN oncology 20110101

• Adaptation to statins restricts human tumour growth in Nude mice.

  BMC cancer 20110101

• Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.

  Molecular cancer 20110101

• Clinical relevance and biology of circulating tumor cells.

  Breast cancer research : BCR 20110101

• Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.

  Breast cancer research : BCR 20110101

• Targeting cholesterol-rich microdomains to circumvent tamoxifen-resistant breast cancer.

  Breast cancer research : BCR 20110101

• Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

  Breast cancer research : BCR 20110101

• Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs.

  PloS one 20110101

• Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations.

  Diagnostic pathology 20110101

• Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.

  Journal of translational medicine 20110101

• Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.

  Health technology assessment (Winchester, England) 20110101

• The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology.

  The International journal of developmental biology 20110101

• Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib?

  Clinical Medicine Insights. Oncology 20110101

• Identifying HER2 inhibitors from natural products database.

  PloS one 20110101

• A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.

  Breast cancer research : BCR 20110101

• Radiotherapy and 'new' drugs-new side effects?

  Radiation oncology (London, England) 20110101

• Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.

  Journal of carcinogenesis 20110101

• Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer.

  Journal of carcinogenesis 20110101

• Genomic sequencing in clinical trials.

  Journal of translational medicine 20110101

• Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells.

  PloS one 20110101

• Luminal-B breast cancer and novel therapeutic targets.

  Breast cancer research : BCR 20110101

• [Novel target therapies used in breast cancer management].

  Voprosy onkologii 20110101

• Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors.

  Frontiers in molecular neuroscience 20110101

• Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?

  Ecancermedicalscience 20110101

• Endocrine-responsive breast cancer: a 28-year Odyssey.

  Ecancermedicalscience 20110101

• Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.

  Chemotherapy research and practice 20110101

• Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer.

  International journal of breast cancer 20110101

• A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data.

  BMC genomics 20110101

• Molecular aspects of breast cancer metastasis to the brain.

  Genetics research international 20110101

• Cell death signaling and anticancer therapy.

  Frontiers in oncology 20110101

• Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.

  Journal of medicinal chemistry 20101223

• Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.

  The Tokai journal of experimental and clinical medicine 20101220

• Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20101215

• Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.

  Oncogene 20101202

• A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer.

  American journal of clinical oncology 20101201

• Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?

  Critical reviews in oncology/hematology 20101201

• Role of anti-Her-2 therapy in bladder carcinoma.

  Journal of cancer research and clinical oncology 20101201

• The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.

  Cancer 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro.

  Toxicology and applied pharmacology 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP.

  Molecular cancer therapeutics 20101201

• Breast cancer and pregnancy: current concepts in diagnosis and treatment.

  The oncologist 20101201

• The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins.

  Anticancer research 20101201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101201

• [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101201

• Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20101201

• Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.

  Cell death & disease 20101201

• Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.

  Chemistry & biology 20101124

• The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

  Cancer biology & therapy 20101115

• Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.

  Japanese journal of clinical oncology 20101101

• Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.

  Current cancer drug targets 20101101

• Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.

  Cancer biology & therapy 20101101

• Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.

  Cancer biology & therapy 20101101

• Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.

  Cancer chemotherapy and pharmacology 20101101

• Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.

  Wiener medizinische Wochenschrift (1946) 20101101

• Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.

  Respiratory care 20101101

• Radiation recall with anticancer agents.

  The oncologist 20101101

• [Principles and method of action of targeted therapies].

  Wiener medizinische Wochenschrift (1946) 20101101

• [Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].

  Gan to kagaku ryoho. Cancer & chemotherapy 20101101

• Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models.

  Immunotherapy 20101101

• Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

  Cancer treatment reviews 20101101

• Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.

  Cancer treatment reviews 20101101

• Lapatinib in breast cancer: clinical experiences and future perspectives.

  Cancer treatment reviews 20101101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20101101

• Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.

  Oncotarget 20101101

• Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinases.

  Bioorganic & medicinal chemistry letters 20101015

• An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines.

  Investigational new drugs 20101001

• Molecular biology of breast cancer stem cells: potential clinical applications.

  Cancer treatment reviews 20101001

• Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.

  Molecular pharmacology 20101001

• Metabolism considerations for kinase inhibitors in cancer treatment.

  Expert opinion on drug metabolism & toxicology 20101001

• Human epidermal growth factor receptor 2 testing in 2010: does chromosome 17 centromere copy number make any difference?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20101001

• Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.

  Cancer science 20101001

• [HER2 ASCO guidelines. The answer to everything?].

  Der Pathologe 20101001

• [Therapeutic targets and molecular mechanisms].

  Nihon rinsho. Japanese journal of clinical medicine 20101001

• [Molecular targeted therapy for breast cancer treatment, challenge to cure].

  Nihon rinsho. Japanese journal of clinical medicine 20101001

• Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours.

  British journal of cancer 20100928

• Cardiac side-effects of cancer chemotherapy.

  International journal of cardiology 20100924

• Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100920

• H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3.

  Oncogene 20100916

• Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.

  British journal of cancer 20100907

• Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

  Breast cancer research and treatment 20100901

• Synthesis and biological evaluation of novel 2,4'-bis substituted diphenylamines as anticancer agents and potential epidermal growth factor receptor tyrosine kinase inhibitors.

  European journal of medicinal chemistry 20100901

• Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.

  Hepatology (Baltimore, Md.) 20100901

• Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100901

• Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.

  The oncologist 20100901

• Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.

  The oncologist 20100901

• Novel cytotoxic backbones and targeted therapies: recent data and ongoing clinical trials.

  Clinical breast cancer 20100901

• [Pharmacological profiles and clinical effects of lapatinib tosilate (Tykerb)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100901

• The epidermal growth factor receptor (EGFR) promotes uptake of influenza A viruses (IAV) into host cells.

  PLoS pathogens 20100901

• Economic/societal burden of metastatic breast cancer: a US perspective.

  The American journal of managed care 20100901

• Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancer.

  The Netherlands journal of medicine 20100901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100901

• GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy.

  Cell death & disease 20100901

• Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.

  Cancer letters 20100828

• A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit.

  British journal of cancer 20100824

• Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.

  British journal of cancer 20100810

• Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study.

  British journal of cancer 20100810

• Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.

  Investigational new drugs 20100801

• EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

  Breast cancer research and treatment 20100801

• Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.

  Critical reviews in oncology/hematology 20100801

• Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.

  Cancer treatment reviews 20100801

• Targeted therapy in breast cancer: current status and future directions.

  Japanese journal of clinical oncology 20100801

• mTOR signaling in glioblastoma: lessons learned from bench to bedside.

  Neuro-oncology 20100801

• Structure-based and ligand-based drug design for HER 2 receptor.

  Journal of biomolecular structure & dynamics 20100801

• ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.

  Neuro-oncology 20100801

• Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100801

• Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

  The oncologist 20100801

• Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib.

  Nature reviews. Clinical oncology 20100801

• Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20100801

• Rational approach to the synthesis, evaluation, and (68)ga labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase.

  Cancer biotherapy & radiopharmaceuticals 20100801

• Lapatinib and breast cancer: current indications and outlook for the future.

  Expert review of anticancer therapy 20100801

• Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.

  Drugs 20100730

• Decoupling of receptor and downstream signals in the Akt pathway by its low-pass filter characteristics.

  Science signaling 20100727

• Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710

• Emerging targeted therapies for breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100710

• HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.

  Breast cancer research and treatment 20100701

• An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100701

• Molecular targeted therapy of biliary tract cancer--results of the first clinical studies.

  Current drug targets 20100701

• Electrophysiological effects of the anti-cancer drug lapatinib on cardiac repolarization.

  Basic & clinical pharmacology & toxicology 20100701

• Trastuzumab in gastric cancer.

  European journal of cancer (Oxford, England : 1990) 20100701

• MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.

  Molecular cancer therapeutics 20100701

• Targeted therapies: Lapatinib is effective in patients with p95HER2-positive tumors.

  Nature reviews. Clinical oncology 20100701

• [Treatment with oral agents for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20100701

• N-[3-Chloro-4-(3-fluoro-benz-yloxy)phen-yl]-6-iodo-quinazolin-4-amine.

  Acta crystallographica. Section E, Structure reports online 20100701

• Probing the probes: fitness factors for small molecule tools.

  Chemistry & biology 20100625

• Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100620

• Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.

  International journal of cancer 20100615

• NICE rejects drug for metastatic breast cancer because of cost and poor efficacy.

  BMJ (Clinical research ed.) 20100611

• Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review.

  Anti-cancer drugs 20100601

• Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.

  Current cancer drug targets 20100601

• EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.

  Expert opinion on emerging drugs 20100601

• Lapatinib in combination with radiation diminishes tumor regrowth in HER2+ and basal-like/EGFR+ breast tumor xenografts.

  International journal of radiation oncology, biology, physics 20100601

• Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

  Molecular cancer therapeutics 20100601

• Targeted therapy in inflammatory breast cancer.

  Cancer 20100601

• Novel targeted therapies in inflammatory breast cancer.

  Cancer 20100601

• Obesity and cancer.

  The oncologist 20100601

• Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel.

  Wiener klinische Wochenschrift 20100601

• Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

  Current oncology (Toronto, Ont.) 20100601

• Manage diarrhea and skin effects from lapatinib.

  ONS connect 20100601

• Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.

  British journal of cancer 20100511

• HER2 as a target for breast cancer therapy.

  Expert opinion on biological therapy 20100501

• Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer.

  Current medical research and opinion 20100501

• Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

  Breast cancer research and treatment 20100501

• Systemic treatment in breast-cancer patients with brain metastasis.

  Expert opinion on pharmacotherapy 20100501

• Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100501

• Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.

  Molecular cancer therapeutics 20100501

• HER2-positive breast cancer: beyond trastuzumab.

  Oncology (Williston Park, N.Y.) 20100430

• Targeting alternative pathways in HER2-positive breast cancer.

  Oncology (Williston Park, N.Y.) 20100430

• Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.

  British journal of cancer 20100427

• Mechanisms of resistance to HER family targeting antibodies.

  Experimental cell research 20100415

• Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases.

  Bioorganic & medicinal chemistry letters 20100415

• EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy.

  British journal of cancer 20100413

• International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

  Journal of the National Cancer Institute 20100407

• Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics.

  Investigational new drugs 20100401

• Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100401

• Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer.

  Current medical research and opinion 20100401

• Antitumor effects of lapatinib (GW572016), a dual inhibitor of EGFR and HER-2, in combination with cisplatin or paclitaxel on head and neck squamous cell carcinoma.

  Oncology reports 20100401

• Reporting of studies on new medicines in major medical journals: a case study in breast cancer.

  Clinical pharmacology and therapeutics 20100401

• Lapatinib side-effect management.

  Clinical journal of oncology nursing 20100401

• One year of complete clinical response in a metastatic breast cancer patient treated with a combination of lapatinib and gemcitabine.

  Current oncology (Toronto, Ont.) 20100401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100401

• Imatinib plasma levels: correlation with clinical benefit in GIST patients.

  British journal of cancer 20100330

• Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.

  British journal of cancer 20100330

• RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

  Nature 20100318

• Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

  British journal of cancer 20100316

• Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.

  Cancer research 20100315

• Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists.

  Cancer research 20100315

• Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100315

• Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.

  Journal of medicinal chemistry 20100311

• Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.

  British journal of cancer 20100302

• Hyponatremia as a prognostic and predictive factor in metastatic renal cell carcinoma.

  British journal of cancer 20100302

• In silico identification of significant detrimental missense mutations of EGFR and their effect with 4-anilinoquinazoline-based drugs.

  Applied biochemistry and biotechnology 20100301

• In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

  Cancer chemotherapy and pharmacology 20100301

• Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• Lapatinib and metronomic capecitabine combination in an HER2-positive inflammatory breast cancer patient: a case report.

  Annals of oncology : official journal of the European Society for Medical Oncology 20100301

• Ras-induced resistance to lapatinib is overcome by MEK inhibition.

  Current cancer drug targets 20100301

• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20100301

• Quantitative proteome and phosphoproteome analyses of cultured cells based on SILAC labeling without requirement of serum dialysis.

  Molecular bioSystems 20100301

• The cardiac safety of trastuzumab in the treatment of breast cancer.

  Expert opinion on drug safety 20100301

• [Management of metastatic HER2-positive breast cancer: present and future].

  Bulletin du cancer 20100301

• Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100301

• Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100301

• Does lapatinib work against HER2-negative breast cancers?

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100301

• Breast cancer drug approved for new indication.

  Women's health (London, England) 20100301

• Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.

  The oncologist 20100301

• HER2 as a cancer stem-cell target.

  The Lancet. Oncology 20100301

• Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.

  Histopathology 20100301

• Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma.

  International journal of cancer 20100215

• Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100215

• AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100215

• In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer.

  Cancer science 20100201

• Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

  Nature reviews. Clinical oncology 20100201

• Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100201

• Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.

  Molecular cancer therapeutics 20100201

• Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls.

  Expert review of anticancer therapy 20100201

• Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.

  The oncologist 20100201

• Updates on therapeutic approaches in HER2-positive disease.

  Clinical advances in hematology & oncology : H&O 20100201

• Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.

  Science translational medicine 20100127

• Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.

  Biochemical pharmacology 20100115

• Role of epidermal growth factor inhibition in experimental pulmonary hypertension.

  American journal of respiratory and critical care medicine 20100115

• Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100115

• Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.

  Journal of the National Cancer Institute 20100106

• A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

  Cancer chemotherapy and pharmacology 20100101

• Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance.

  Annals of surgical oncology 20100101

• Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer.

  The breast journal 20100101

• Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

  Journal of oncology 20100101

• Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias.

  International journal of technology assessment in health care 20100101

• Targeting the EGF receptor for ovarian cancer therapy.

  Journal of oncology 20100101

• A current review of targeted therapeutics for ovarian cancer.

  Journal of oncology 20100101

• Lapatinib.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101

• Targeted therapies in epithelial ovarian cancer.

  Journal of oncology 20100101

• Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.

  PloS one 20100101

• Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?

  Obstetrics and gynecology international 20100101

• Targeted HER2 treatment in advanced gastric cancer.

  Oncology 20100101

• Pharmacoeconomic evaluation in Ireland: a review of the process.

  PharmacoEconomics 20100101

• Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.

  PloS one 20100101

• Molecular profiling of endometrial malignancies.

  Obstetrics and gynecology international 20100101

• Cancer-drug associations: a complex system.

  PloS one 20100101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20100101

• Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

  Molecular cancer 20100101

• Molecular targeted therapies in head and neck cancer--an update of recent developments-.

  Head & neck oncology 20100101

• A comprehensive molecular interaction map for rheumatoid arthritis.

  PloS one 20100101

• Are tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?

  Swiss medical weekly 20100101

• High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.

  Breast cancer research : BCR 20100101

• Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

  BMC cancer 20100101

• Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.

  Breast cancer research : BCR 20100101

• Anthracenedione derivatives as anticancer agents isolated from secondary metabolites of the mangrove endophytic fungi.

  Marine drugs 20100101

• Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.

  Head & neck oncology 20100101

• Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.

  BMC cancer 20100101

• Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

  BMC health services research 20100101

• Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques.

  BMC bioinformatics 20100101

• An algorithm for classifying tumors based on genomic aberrations and selecting representative tumor models.

  BMC medical genomics 20100101

• RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

  Breast cancer research : BCR 20100101

• [Novel targeted drug therapies in breast cancer].

  Duodecim; laaketieteellinen aikakauskirja 20100101

• HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.

  Breast cancer research : BCR 20100101

• Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity.

  BMC cancer 20100101

• Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization.

  Diagnostic pathology 20100101

• Personalized therapies in the cancer 'omics' era.

  Molecular cancer 20100101

• Epidermal growth factor receptor tyrosine kinase inhibitors for elderly patients with advanced non-small cell lung cancer.

  Current gerontology and geriatrics research 20100101

• Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.

  Clinical Medicine Insights. Oncology 20100101

• Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma.

  Biologics : targets & therapy 20100101

• The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches.

  Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20100101

• L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions.

  BMC molecular biology 20100101

• [Metastatic breast cancer in 28 years old man].

  Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 20100101

• Rapid-Onset Acute Respiratory Distress Syndrome (ARDS) in a Patient Undergoing Metastatic Liver Resection: A Case Report and Review of the Literature.

  Anesthesiology research and practice 20100101

• Molecular biomarker analyses using circulating tumor cells.

  PloS one 20100101

• Oral systemic therapy: Not all 'win-win'.

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101

• NEO adjuvant chemotherapy in breast cancer: What have we learned so far?

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101

• Genome profiling of ERBB2-amplified breast cancers.

  BMC cancer 20100101

• Angiogenesis and breast cancer.

  Journal of oncology 20100101

• Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype.

  BMC cancer 20100101

• Pazopanib for the treatment of patients with advanced renal cell carcinoma.

  Clinical Medicine Insights. Oncology 20100101

• RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab.

  Radiation oncology (London, England) 20100101

• New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib.

  OncoTargets and therapy 20100101

• Present and future evolution of advanced breast cancer therapy.

  Breast cancer research : BCR 20100101

• Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone.

  Breast cancer research : BCR 20100101

• Antiangiogenic therapy for breast cancer.

  Breast cancer research : BCR 20100101

• Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.

  The breast journal 20100101

• Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.

  Breast cancer research : BCR 20100101

• Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.

  BMC cancer 20100101

• A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer.

  Oncology 20100101

• The emerging role of nimotuzumab in the treatment of non-small cell lung cancer.

  Biologics : targets & therapy 20100101

• The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.

  BMC cancer 20100101

• Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens.

  Pathology research international 20100101

• Are current development programs realising the full potential of new agents?

  Breast cancer research : BCR 20100101

• Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry.

  Breast cancer research : BCR 20100101

• Markers of tumor-initiating cells predict chemoresistance in breast cancer.

  PloS one 20100101

• Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.

  Cancer management and research 20100101

• Breast cancer in low- and middle-income countries: an emerging and challenging epidemic.

  Journal of oncology 20100101

• Cancer management in the twenty-first century in India.

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101

• Breast cancer (metastatic).

  BMJ clinical evidence 20100101

• Pharmacoeconomic considerations in the treatment of breast cancer.

  ClinicoEconomics and outcomes research : CEOR 20100101

• The role of funding and policies on innovation in cancer drug development.

  Ecancermedicalscience 20100101

• Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091220

• The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.

  International journal of cancer 20091215

• EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.

  Science signaling 20091215

• Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.

  Oncogene 20091203

• Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.

  Cancer treatment reviews 20091201

• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  Cancer treatment reviews 20091201

• Geographic distribution of lapatinib-induced skin rash: sparing of abdominal skin persists in the transverse rectus abdominis myocutaneous flap.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091201

• Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.

  Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20091201

• Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091201

• Current combination chemotherapy regimens for metastatic breast cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20091201

• Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091201

• Small-molecule inhibitors of the human epidermal receptor family.

  Expert opinion on investigational drugs 20091201

• Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.

  Pharmacotherapy 20091201

• Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data.

  PLoS computational biology 20091201

• [Lapatinib treatment-option in trastuzumab-resistant breast cancer].

  Magyar onkologia 20091201

• [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].

  Gan to kagaku ryoho. Cancer & chemotherapy 20091201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20091201

• How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091120

• Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies.

  British journal of cancer 20091117

• Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.

  Journal of medicinal chemistry 20091112

• Lapatinib as a chemotherapeutic drug.

  Recent patents on anti-cancer drug discovery 20091101

• Trastuzumab versus lapatinib: the cardiac side of the story.

  Cancer treatment reviews 20091101

• Lapatinib: a competitor or companion to trastuzumab?

  Cancer treatment reviews 20091101

• Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines.

  Anti-cancer drugs 20091101

• Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.

  Expert opinion on investigational drugs 20091101

• Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.

  Cancer biology & therapy 20091101

• A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20091101

• Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

  Anti-cancer drugs 20091101

• Lapatinib in metastatic breast cancer.

  Women's health (London, England) 20091101

• Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer.

  Neoplasia (New York, N.Y.) 20091101

• Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer.

  The oncologist 20091101

• Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.

  Expert review of anticancer therapy 20091101

• Autophagy can contribute to cell death when combining targeted therapy.

  Cancer biology & therapy 20091101

• Lapatinib: a review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer.

  Drugs 20091022

• Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.

  British journal of cancer 20091020

• Gastric cancer: trastuzumab trial results spur search for other targets.

  Journal of the National Cancer Institute 20091007

• An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom.

  British journal of cancer 20091006

• Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.

  Breast cancer research and treatment 20091001

• Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.

  Pediatric blood & cancer 20091001

• Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.

  Oral oncology 20091001

• Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

  Nature genetics 20091001

• Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.

  Journal of Korean medical science 20091001

• Targeted therapy of metastatic breast cancer.

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20091001

• Lapatinib for the treatment of HER2-overexpressing breast cancer.

  Health technology assessment (Winchester, England) 20091001

• Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?

  Oncology (Williston Park, N.Y.) 20091001

• Targeting breast cancer stem cells.

  Breast (Edinburgh, Scotland) 20091001

• A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090915

• A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.

  Cancer chemotherapy and pharmacology 20090901

• Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Target-based therapies in breast cancer: current status and future perspectives.

  Endocrine-related cancer 20090901

• Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.

  Current opinion in oncology 20090901

• Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090901

• Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL.

  Cancer research 20090901

• A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090901

• The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

  Targeted oncology 20090901

• Personalizing therapy for metastatic breast cancer.

  Expert review of anticancer therapy 20090901

• What's positive about 'triple-negative' breast cancer?

  Future oncology (London, England) 20090901

• The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.

  Current oncology (Toronto, Ont.) 20090901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090901

• Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.

  Sao Paulo medical journal = Revista paulista de medicina 20090901

• Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090820

• [Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090810

• Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib.

  Head & neck 20090801

• Mechanisms of resistance to EGFR inhibitors in head and neck cancer.

  Head & neck 20090801

• Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.

  Cancer science 20090801

• Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090801

• Effects of food on bioavailability of lapatinib: useful data, wrong conclusion.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090801

• Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

  Cancer research 20090801

• Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.

  Molecular cancer therapeutics 20090801

• The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.

  Current oncology (Toronto, Ont.) 20090801

• Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.

  PLoS computational biology 20090801

• Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.

  Clinical therapeutics 20090801

• In vitro enzymatic characterization of near full length EGFR in activated and inhibited states.

  Biochemistry 20090721

• Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090715

• An analysis of current pharmaceutical industry practices for making clinical trial results publicly accessible.

  Contemporary clinical trials 20090701

• A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

  Cancer 20090701

• Molecular targets for treatment of inflammatory breast cancer.

  Nature reviews. Clinical oncology 20090701

• FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

  International journal of oncology 20090701

• mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

  Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20090701

• [Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090701

• Treatment of brain metastases in patients with HER2+ breast cancer.

  Advances in therapy 20090701

• Information for patients. HER2: what you need to know.

  Oncology (Williston Park, N.Y.) 20090701

• Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor.

  The Journal of biological chemistry 20090619

• Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090615

• Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.

  Annals of oncology : official journal of the European Society for Medical Oncology 20090601

• Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.

  The Lancet. Oncology 20090601

• ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

• Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR.

  Current opinion in molecular therapeutics 20090601

• Lapatinib for inflammatory breast cancer.

  The Lancet. Oncology 20090601

• Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.

  Nature reviews. Clinical oncology 20090601

• Enhancing the efficacy of hormonal agents with selected targeted agents.

  Clinical breast cancer 20090601

• Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.

  Biochemical pharmacology 20090515

• Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer.

  Cancer research 20090515

• Dual targeting of EGFR and HER-2 in colon cancer cell lines.

  Cancer chemotherapy and pharmacology 20090501

• Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.

  The American journal of surgical pathology 20090501

• No cure in sight for the world's drug problem.

  The Lancet. Oncology 20090501

• Medicinal chemistry strategies in follow-on drug discovery.

  Drug discovery today 20090501

• HER-2 signaling and inhibition in breast cancer.

  Current cancer drug targets 20090501

• [The progress of second-line chemotherapy and molecular targeting agents in gastric cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• [Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].

  Gan to kagaku ryoho. Cancer & chemotherapy 20090501

• Lapatinib plus paclitaxel as first-line therapy for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: inappropriate conclusions from a company-sponsored study?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090410

• Treatment of metastatic breast cancer: looking towards the future.

  Breast cancer research and treatment 20090401

• Analysis of dermatologic events in patients with cancer treated with lapatinib.

  Breast cancer research and treatment 20090401

• Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment.

  Journal of cancer research and clinical oncology 20090401

• HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

  Cancer treatment reviews 20090401

• Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.

  International journal of oncology 20090401

• Trastuzumab before breast surgery? Large trial says yes but does not quell debate.

  Journal of the National Cancer Institute 20090401

• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  The oncologist 20090401

• Hidden HER-2/neu-positive breast cancer: how to maximize detection.

  IDrugs : the investigational drugs journal 20090401

• Therapeutic options for metastatic breast cancer.

  Expert opinion on pharmacotherapy 20090401

• Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects.

  British journal of clinical pharmacology 20090401

• Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).

  Seminars in oncology 20090401

• Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?

  Targeted oncology 20090401

• Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.

  British journal of cancer 20090324

• Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients.

  British journal of cancer 20090324

• Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090315

• microRNA-205 regulates HER3 in human breast cancer.

  Cancer research 20090315

• Unilateral taxane-induced onychopathy in a patient with a brain metastasis.

  Dermatology online journal 20090315

• Effects of food on the relative bioavailability of lapatinib in cancer patients.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310

• Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090310

• Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090301

• Stemming resistance to HER-2 targeted therapy.

  Journal of mammary gland biology and neoplasia 20090301

• Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

  Current cancer drug targets 20090301

• [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].

  Magyar onkologia 20090301

• Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.

  Drug news & perspectives 20090301

• Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.

  Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia 20090301

• An overview of HER-targeted therapy with lapatinib in breast cancer.

  Advances in therapy 20090301

• Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas.

  British journal of cancer 20090224

• Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20090215

• Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity.

  Oncogene 20090212

• Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.

  Japanese journal of clinical oncology 20090201

• An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016).

  Drug metabolism and disposition: the biological fate of chemicals 20090201

• Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

  Bioorganic & medicinal chemistry letters 20090201

• Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer.

  Cancer 20090201

• Protein kinase inhibitors: contributions from structure to clinical compounds.

  Quarterly reviews of biophysics 20090201

• Lapatinib: new drug. For some women with metastatic breast cancer.

  Prescrire international 20090201

• Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.

  Journal of the National Cancer Institute 20090121

• Molecular therapy for the treatment of hepatocellular carcinoma.

  British journal of cancer 20090113

• HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

  British journal of cancer 20090113

• How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090110

• Ten years of HER2-directed therapy: still questions after all these years.

  Breast cancer research and treatment 20090101

• New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer.

  Nature clinical practice. Oncology 20090101

• Integrating biologically targeted therapy in head and neck squamous cell carcinomas.

  Seminars in radiation oncology 20090101

• Synthesis and biological evaluation of novel 2,4,5-substituted pyrimidine derivatives for anticancer activity.

  Bioorganic & medicinal chemistry letters 20090101

• Acute paronychia caused by lapatinib therapy.

  Clinical and experimental dermatology 20090101

• Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer.

  Critical care medicine 20090101

• San Antonio Breast Cancer Symposium.

  The Lancet. Oncology 20090101

• Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.

  BMC systems biology 20090101

• Tyrosine kinase blockers: new hope for successful cancer therapy.

  Anti-cancer agents in medicinal chemistry 20090101

• Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data.

  Molecular systems biology 20090101

• How to deal with large models?

  Molecular systems biology 20090101

• Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

  Breast cancer research : BCR 20090101

• Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

  Breast cancer research : BCR 20090101

• Prognostic indices for brain metastases--usefulness and challenges.

  Radiation oncology (London, England) 20090101

• Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma.

  Head & neck oncology 20090101

• Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.

  American journal of therapeutics 20090101

• Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents.

  Breast cancer research : BCR 20090101

• Prognostic scores in brain metastases from breast cancer.

  BMC cancer 20090101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20090101

• Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.

  PloS one 20090101

• Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.

  Journal of oncology 20090101

• The 'win-win' initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.

  World journal of surgical oncology 20090101

• Use of probiotics in the management of chemotherapy-induced diarrhea: a case study.

  JPEN. Journal of parenteral and enteral nutrition 20090101

• Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.

  Journal of oncology 20090101

• MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

  Breast cancer research : BCR 20090101

• Challenging issues in molecular-targeted therapy.

  Therapeutics and clinical risk management 20090101

• Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target.

  PloS one 20090101

• Immunohistochemical characterization of subtypes of male breast carcinoma.

  Breast cancer research : BCR 20090101

• Targeting targeted agents: open issues for clinical trial design.

  Journal of experimental & clinical cancer research : CR 20090101

• Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.

  BMC cancer 20090101

• Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

  Breast cancer research : BCR 20090101

• Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.

  PloS one 20090101

• HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005.

  Breast cancer research : BCR 20090101

• Neurofibromatosis type 2 (NF2): a clinical and molecular review.

  Orphanet journal of rare diseases 20090101

• No incidence of BRAF mutations in salivary gland carcinomas--implications for anti-EGFR therapies.

  Journal of biomedicine & biotechnology 20090101

• Breast cancer stem cells: tools and models to rely on.

  BMC cancer 20090101

• Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.

  BMC cancer 20090101

• Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

  Breast cancer research : BCR 20090101

• Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.

  Cancer treatment and research 20090101

• Costs of adjuvant breast cancer treatments.

  Cancer treatment and research 20090101

• Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.

  PloS one 20090101

• Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors.

  Journal of oncology 20090101

• MicroRNAs as New Players for Diagnosis, Prognosis, and Therapeutic Targets in Breast Cancer.

  Journal of oncology 20090101

• Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.

  Breast cancer research : BCR 20090101

• EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab.

  Biologics : targets & therapy 20090101

• HER2 breast cancer therapies: a review.

  Biologics : targets & therapy 20090101

• Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.

  BMC cancer 20090101

• Cardiotoxicity induced by tyrosine kinase inhibitors.

  Acta oncologica (Stockholm, Sweden) 20090101

• Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

  Breast cancer research : BCR 20090101

• Update on Anti-EGFR Therapy.

  Journal of oncology 20090101

• Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

  Breast cancer research : BCR 20090101

• Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

  Biologics : targets & therapy 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin.

  Breast cancer : basic and clinical research 20090101

• HPV & head and neck cancer: a descriptive update.

  Head & neck oncology 20090101

• Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.

  BMC cancer 20090101

• Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

  PloS one 20090101

• Epithelial to mesenchymal transition and breast cancer.

  Breast cancer research : BCR 20090101

• Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients.

  Breast cancer research : BCR 20090101

• Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases.

  PloS one 20090101

• Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8.

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? The scenario.

  Breast cancer research : BCR 20090101

• Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.

  Breast cancer research : BCR 20090101

• Tailored targeted therapy for all: a realistic and worthwhile objective?

  Breast cancer research : BCR 20090101

• Tailored targeted therapy for all: a realistic and worthwhile objective against.

  Breast cancer research : BCR 20090101

• Protein modifications as potential biomarkers in breast cancer.

  Biomarker insights 20090101

• Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.

  Clinical therapeutics 20090101

• Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.

  Clinical therapeutics 20090101

• EGFR signaling and drug discovery.

  Oncology 20090101

• [Role of adjuvant chemotherapy in the choice of chemotherapeutic treatment of metastatic breast cancer].

  La Clinica terapeutica 20090101

• Multiple roles and therapeutic implications of Akt signaling in cancer.

  OncoTargets and therapy 20090101

• Emerging technologies for the genomic analysis of cancer.

  F1000 biology reports 20090101

• HER2 status and breast cancer therapy: recent advances.

  F1000 medicine reports 20090101

• Aromatase inhibitor strategies in metastatic breast cancer.

  International journal of women's health 20090101

• Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer.

  Breast cancer : basic and clinical research 20090101

• The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.

  Cancer letters 20081218

• Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.

  Journal of the National Cancer Institute 20081217

• [Brain metastases in breast cancer: a special disease course for HER2 positive tumors].

  Nederlands tijdschrift voor geneeskunde 20081213

• A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

  Breast cancer research and treatment 20081201

• Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081201

• Targeted therapies in breast cancer: where are we now?

  European journal of cancer (Oxford, England : 1990) 20081201

• Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

  Journal of mammary gland biology and neoplasia 20081201

• Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.

  Current opinion in investigational drugs (London, England : 2000) 20081201

• Jumping higher: is it still possible? The ALTTO trial challenge.

  Expert review of anticancer therapy 20081201

• HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081201

• Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081201

• Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor.

  Cancer research 20081201

• Vinflunine in the treatment of bladder cancer.

  Therapeutics and clinical risk management 20081201

• Small molecule tyrosine kinase inhibitors in pancreatic cancer.

  Biologics : targets & therapy 20081201

• Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

  Cancer research 20081115

• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  Cancer research 20081115

• Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

  British journal of cancer 20081104

• Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.

  Breast cancer research and treatment 20081101

• Tufted hair folliculitis in a woman treated with lapatinib for breast cancer.

  Clinical and experimental dermatology 20081101

• Lapatinib therapy for patients with advanced renal cell carcinoma.

  Nature clinical practice. Oncology 20081101

• Are volumetric changes of brain metastases the best evaluation of efficacy?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081101

• Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20081101

• [Stem cell-targeted therapy--a new strategy for cancer treatment].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20081101

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20081101

• Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.

  The Biochemical journal 20081015

• Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.

  Clinical & experimental metastasis 20081001

• [Targeted therapy for metastatic bladder cancer].

  Der Urologe. Ausg. A 20081001

• A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

  Gynecologic oncology 20081001

• Novel human antibody therapeutics: the age of the Umabs.

  Biotechnology journal 20081001

• HER-2-positive metastatic breast cancer: trastuzumab and beyond.

  Expert opinion on pharmacotherapy 20081001

• EGFR inhibition as a therapy for head and neck squamous cell carcinoma.

  Expert opinion on investigational drugs 20081001

• Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.

  International journal of molecular medicine 20081001

• Lapatinib and ixabepilone for the treatment of metastatic breast cancer.

  Pharmacotherapy 20081001

• Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

  Cancer research 20081001

• Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.

  Health technology assessment (Winchester, England) 20081001

• FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.

  The oncologist 20081001

• Unraveling the biologic and clinical complexities of HER2.

  Clinical breast cancer 20081001

• Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.

  Clinical breast cancer 20081001

• Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities.

  Current pharmaceutical design 20081001

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20081001

• Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

  British journal of cancer 20080916

• Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080915

• Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.

  European journal of pharmacology 20080904

• Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer.

  British journal of cancer 20080902

• Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.

  Molecular pharmacology 20080901

• Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

  Nature clinical practice. Oncology 20080901

• Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report.

  Anti-cancer drugs 20080901

• Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.

  Cancer research 20080901

• [Novel targeting therapy concept for breast cancer treatment].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20080901

• [New period of systemic treatment for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080901

• Evolving therapies in the treatment of hepatocellular carcinoma.

  Biologics : targets & therapy 20080901

• As metastasis yields its biological secrets, researchers hope to apply findings.

  Journal of the National Cancer Institute 20080806

• Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.

  Journal of the National Cancer Institute 20080806

• Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma.

  Hepatology research : the official journal of the Japan Society of Hepatology 20080801

• Drug development in the targeted therapy era.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080801

• Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

  Clinical therapeutics 20080801

• A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080715

• Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710

• Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080710

• Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.

  British journal of cancer 20080708

• Focus on ERBB2.

  Pharmacogenomics 20080701

• Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells.

  Molecular cancer therapeutics 20080701

• Major Advances in the Treatment of Cancer: What does a Non-Oncologist need to know?

  Sultan Qaboos University medical journal 20080701

• Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.

  Oncogene 20080626

• Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach.

  Journal of medicinal chemistry 20080626

• Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080620

• Mathematics in the realm of lapatinib: 500 + 500 = 1,500?

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080620

• Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080620

• Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.

  The Prostate 20080615

• Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells.

  Cell cycle (Georgetown, Tex.) 20080615

• A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080601

• Cerebellar toxicity with capecitabine in a patient with metastatic breast cancer.

  Clinical oncology (Royal College of Radiologists (Great Britain)) 20080601

• [Oncology 2008].

  Deutsche medizinische Wochenschrift (1946) 20080601

• Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials.

  Mayo Clinic proceedings 20080601

• HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?

  Anti-cancer agents in medicinal chemistry 20080601

• Molecularly targeted therapy in breast cancer: the new generation.

  Recent patents on anti-cancer drug discovery 20080601

• Lapatinib study supports cancer stem cell hypothesis, encourages industry research.

  Journal of the National Cancer Institute 20080521

• Treatment-experienced breast cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080515

• Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080510

• Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

  Journal of the National Cancer Institute 20080507

• Issues and controversies in the treatment of HER2 positive metastatic breast cancer.

  Breast cancer research and treatment 20080501

• [Combined chemotherapy with molecular-targeted agent for breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20080501

• Therapeutic options in the management of metastatic breast cancer.

  Oncology (Williston Park, N.Y.) 20080501

• [Advances in research on treatment of breast cancer with lapatinib].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20080501

• Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080420

• EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080415

• Emerging therapeutic options for breast cancer chemotherapy during pregnancy.

  Annals of oncology : official journal of the European Society for Medical Oncology 20080401

• The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

  Drug metabolism and disposition: the biological fate of chemicals 20080401

• Structure and clinical relevance of the epidermal growth factor receptor in human cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080401

• Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.

  American journal of clinical oncology 20080401

• Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.

  Seminars in oncology 20080401

• Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.

  Molecular cancer therapeutics 20080401

• Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

  The oncologist 20080401

• Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB Trial).

  Clinical breast cancer 20080401

• [New treatment approaches in breast cancer].

  Therapeutische Umschau. Revue therapeutique 20080401

• Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

  British journal of cancer 20080325

• Treatment of breast cancer with trastuzumab during pregnancy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080320

• Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.

  Bioorganic & medicinal chemistry letters 20080315

• Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts.

  Annals of the rheumatic diseases 20080301

• Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080301

• Mechanism of activation and inhibition of the HER4/ErbB4 kinase.

  Structure (London, England : 1993) 20080301

• Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.

  Molecular cancer therapeutics 20080301

• Systemic therapies for recurrent and/or metastatic salivary gland cancers.

  Expert review of anticancer therapy 20080301

• [The new generation of breast cancer clinical trials: the right drug for the right target].

  Bulletin du cancer 20080301

• Lapatinib: a sword with two edges.

  Pathology oncology research : POR 20080301

• Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.

  Clinical breast cancer 20080301

• Cardiac toxicity of ErbB2-targeted therapies: what do we know?

  Clinical breast cancer 20080301

• Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer.

  Biologics : targets & therapy 20080301

• Erlotinib in the treatment of advanced pancreatic cancer.

  Biologics : targets & therapy 20080301

• Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells.

  Cell proliferation 20080201

• Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.

  Future oncology (London, England) 20080201

• The medical treatment of inflammatory breast cancer.

  Seminars in oncology 20080201

• Advances in HER2-positive breast cancer.

  Clinical advances in hematology & oncology : H&O 20080201

• European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.

  Breast (Edinburgh, Scotland) 20080201

• Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).

  Clinical breast cancer 20080201

• Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.

  British journal of cancer 20080129

• [Metastatic breast cancer--new methods of treatment].

  MMW Fortschritte der Medizin 20080117

• A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.

  British journal of cancer 20080115

• Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

  Cancer research 20080115

• SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.

  Anti-cancer drugs 20080101

• Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers.

  BMC cancer 20080101

• A quantitative analysis of kinase inhibitor selectivity.

  Nature biotechnology 20080101

• Considerations in treatment choice for metastatic breast cancer.

  Breast cancer (Tokyo, Japan) 20080101

• Development of new targeted therapies for breast cancer.

  Breast cancer (Tokyo, Japan) 20080101

• From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.

  Current medicinal chemistry 20080101

• Cell signaling modifiers in prostate cancer.

  Cancer journal (Sudbury, Mass.) 20080101

• Preclinical and clinical studies of novel breast cancer drugs targeting molecules involved in protein kinase C signaling, the putative metastasis-suppressor gene Cap43 and the Y-box binding protein-1.

  Current medicinal chemistry 20080101

• Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling.

  Cancer cell international 20080101

• The emerging role of lapatinib in HER2-positive breast cancer.

  Current oncology reports 20080101

• PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.

  Breast cancer research : BCR 20080101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080101

• Chemotherapy for metastatic gastric cancer: past, present, and future.

  Journal of gastroenterology 20080101

• Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer.

  Breast cancer research : BCR 20080101

• Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.

  BMC cancer 20080101

• Breast cancer stem cells: implications for therapy of breast cancer.

  Breast cancer research : BCR 20080101

• Molecular targeted therapies for breast cancer treatment.

  Breast cancer research : BCR 20080101

• Promising newer molecular-targeted therapies in head and neck cancer.

  Drugs 20080101

• HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

  PloS one 20080101

• Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.

  Journal of translational medicine 20080101

• Novel therapies in genitourinary cancer: an update.

  Journal of hematology & oncology 20080101

• Targeting Her-2/neu in breast cancer: as easy as this!

  Oncology 20080101

• Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.

  PloS one 20080101

• ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.

  Breast cancer research : BCR 20080101

• The impact of functional imaging on radiation medicine.

  Radiation oncology (London, England) 20080101

• Neuropsychological testing and biomarkers in the management of brain metastases.

  Radiation oncology (London, England) 20080101

• EGFR expression in gallbladder carcinoma in North America.

  International journal of medical sciences 20080101

• Presentation and course of brain metastases from breast cancer in a paranoid-schizophrenic patient: A case report.

  Cases journal 20080101

• Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature.

  Journal of medical case reports 20080101

• Novel therapies in breast cancer: what is new from ASCO 2008.

  Journal of hematology & oncology 20080101

• EGFR-targeted therapeutics: focus on SCCHN and NSCLC.

  TheScientificWorldJournal 20080101

• ErbB3 is required for ductal morphogenesis in the mouse mammary gland.

  Breast cancer research : BCR 20080101

• The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.

  PloS one 20080101

• ErbB antagonists patenting: 'playing chess with cancer'.

  Recent patents on biotechnology 20080101

• Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.

  Molecular cancer 20080101

• Putative growth characteristics of micrometastatic breast cancer.

  Breast cancer research : BCR 20080101

• tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO).

  BMC cancer 20080101

• The management of cancer in the elderly: targeted therapies in oncology.

  Immunity & ageing : I & A 20080101

• Integration of endocrine therapy with targeted agents.

  Breast cancer research : BCR 20080101

• Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.

  Breast cancer research : BCR 20080101

• Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.

  Drug design, development and therapy 20080101

• The epidermal growth factor receptor family in breast cancer.

  OncoTargets and therapy 20080101

• Targeted treatment of advanced and metastaticbreast cancer with lapatinib.

  OncoTargets and therapy 20080101

• Innovations in chemotherapy and radiation therapy: Implications and opportunities for the Asia-Pacific Rim.

  Biomedical imaging and intervention journal 20080101

• Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation.

  Clinical medicine. Oncology 20080101

• Long survival in a patient with brain metastases from breast cancer.

  Clinical medicine. Oncology 20080101

• A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20071201

• Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.

  Radiology 20071201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20071201

• Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.

  Clinical breast cancer 20071201

• Review article optimizing the use of her-2/neu targeting agents in breast cancer : a developing nation perspective.

  Journal of the Egyptian National Cancer Institute 20071201

• The value of label recommendations: how to dose lapatinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120

• Effect of food on lapatinib pharmacokinetics.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120

• The value meal: effect of food on lapatinib bioavailability.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120

• Controversies in using lapatinib at reduced dosage with food.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071120

• Overcoming treatment challenges in advanced breast cancer.

  Seminars in oncology nursing 20071101

• Choosing the appropriate breast cancer therapy for today's breast cancer patient.

  Seminars in oncology nursing 20071101

• The patient experience.

  Breast cancer research and treatment 20071001

• Femara and the future: tailoring treatment and combination therapies with Femara.

  Breast cancer research and treatment 20071001

• [Trastuzumab and blood-brain barrier].

  Bulletin du cancer 20071001

• Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.

  Oncology (Williston Park, N.Y.) 20071001

• FDA approves new drug for specific type of advanced breast cancer.

  Mayo Clinic women's healthsource 20071001

• Biology of interactions: antiepidermal growth factor receptor agents.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070910

• Lapatinib (Tykerb) for advanced breast cancer.

  The Medical letter on drugs and therapeutics 20070910

• [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].

  Ugeskrift for laeger 20070910

• Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.

  Oral oncology 20070901

• Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.

  Expert opinion on pharmacotherapy 20070901

• Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901

• A multidisciplinary approach to the management of breast cancer, part 2: therapeutic considerations.

  Mayo Clinic proceedings 20070901

• Dissecting kinase signaling pathways.

  Drug discovery today 20070901

• Lapatinib in the treatment of breast cancer.

  Expert review of anticancer therapy 20070901

• HER2 targeted therapy in breast cancer...beyond Herceptin.

  Reviews in endocrine & metabolic disorders 20070901

• Integrating biological agents into systemic therapy of breast cancer: trastuzumab, lapatinib, bevacizumab.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901

• Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.

  Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20070901

• Clinical activities of the epidermal growth factor receptor family inhibitors in breast cancer.

  Biologics : targets & therapy 20070901

• The molecular genetics of breast cancer and targeted therapy.

  Biologics : targets & therapy 20070901

• Targeting HER proteins in cancer therapy and the role of the non-target HER3.

  British journal of cancer 20070820

• Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070820

• Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070815

• The value meal: how to save $1,700 per month or more on lapatinib.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070810

• Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines.

  Cell proliferation 20070801

• Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070801

• Food effects on oral agents.

  Clinical advances in hematology & oncology : H&O 20070801

• A review of lapatinib ditosylate in the treatment of refractory or advanced breast cancer.

  Therapeutics and clinical risk management 20070801

• Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?

  Nature clinical practice. Oncology 20070701

• EGFR targeting of solid tumors.

  Cancer control : journal of the Moffitt Cancer Center 20070701

• Targeted therapy for renal cell carcinoma: a new treatment paradigm.

  Proceedings (Baylor University. Medical Center) 20070701

• Lapatinib-associated toxicity and practical management recommendations.

  The oncologist 20070701

• [Breast cancer and Her-2].

  Nihon rinsho. Japanese journal of clinical medicine 20070628

• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070601

• Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification.

  Cancer research 20070601

• Her signaling in pancreatic cancer.

  Expert opinion on biological therapy 20070601

• Lapatinib in breast cancer.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070601

• Lapatinib.

  Nature reviews. Drug discovery 20070601

• Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer.

  Clinical advances in hematology & oncology : H&O 20070601

• Combination treatment with Grb7 peptide and Doxorubicin or Trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells.

  British journal of cancer 20070521

• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.

  Nature reviews. Cancer 20070501

• Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers.

  Expert review of molecular diagnostics 20070501

• Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.

  Molecular cancer therapeutics 20070501

• Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions.

  Reviews on recent clinical trials 20070501

• Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

  Journal of the National Cancer Institute 20070418

• Lapatinib plus capecitabine in breast cancer.

  The New England journal of medicine 20070405

• Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.

  Nature chemical biology 20070401

• Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials.

  The oncologist 20070401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070401

• Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.

  British journal of cancer 20070326

• Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.

  Journal of the National Cancer Institute 20070307

• The EGF receptor Hokey-Cokey.

  Cancer cell 20070301

• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  Cancer cell 20070301

• Novel approaches to advanced breast cancer: bevacizumab and lapatinib.

  Journal of the National Comprehensive Cancer Network : JNCCN 20070301

• First line targeted therapies in breast cancer: focus on bevacizumab.

  Biologics : targets & therapy 20070301

• Trastuzumab in the management of early and advanced stage breast cancer.

  Biologics : targets & therapy 20070301

• Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.

  British journal of cancer 20070212

• Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.

  Annals of surgical oncology 20070201

• The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.

  Cancer treatment reviews 20070201

• Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.

  Oncology reports 20070201

• Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

  European journal of cancer (Oxford, England : 1990) 20070201

• Recent advances in the therapy of renal cancer.

  Expert opinion on biological therapy 20070201

• Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity.

  Expert opinion on biological therapy 20070201

• European Society for Medical Oncology 2006: meeting highlights on targeted therapies. Istanbul, Turkey, 29 September-3 October 2006.

  Expert opinion on biological therapy 20070201

• Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers.

  Cancer research 20070201

• Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

  Molecular cancer therapeutics 20070201

• Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.

  Urology 20070201

• TEACH: Tykerb evaluation after chemotherapy.

  Clinical breast cancer 20070201

• The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.

  Current treatment options in oncology 20070201

• Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity.

  British journal of cancer 20070129

• Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.

  Japanese journal of clinical oncology 20070101

• HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks.

  Breast cancer research : BCR 20070101

• Therapeutic advances in the treatment of brain metastases.

  Clinical advances in hematology & oncology : H&O 20070101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20070101

• Targeted therapy of breast cancer.

  Current pharmaceutical design 20070101

• Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.

  BMC cancer 20070101

• HER-2-positive breast cancer: hope beyond trastuzumab.

  BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 20070101

• relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.

  Theoretical biology & medical modelling 20070101

• Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.

  Breast cancer (Tokyo, Japan) 20070101

• Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?

  Breast cancer (Tokyo, Japan) 20070101

• Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.

  BMC cancer 20070101

• New drugs: aliskiren hemifumarate, lisdexamfetamine dimesylate, and lapatinib.

  Journal of the American Pharmacists Association : JAPhA 20070101

• Pharmacology of epidermal growth factor inhibitors.

  The International journal of biological markers 20070101

• Rationale and clinical results of multi-target treatments in oncology.

  The International journal of biological markers 20070101

• Molecular targeted therapies in breast cancer: where are we now?

  The international journal of biochemistry & cell biology 20070101

• HER2-positive breast cancer: current and future treatment strategies.

  Drugs 20070101

• HER-2/neu diagnostics in breast cancer.

  Breast cancer research : BCR 20070101

• EGFR and HER-2 antagonists in breast cancer.

  Anticancer research 20070101

• Lapatinib shows promise for inflammatory breast cancer.

  Cancer biology & therapy 20070101

• Targeting the epidermal growth factor receptor in colorectal carcinoma.

  Cancer nursing 20070101

• Targeted therapies in breast cancer: challenging questions from oncology nurses.

  ONS connect 20070101

• EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

  Drugs 20070101

• Lapatinib.

  Drugs 20070101

• Why are promising new drugs for dying patients still out of reach?

  MedGenMed : Medscape general medicine 20070101

• Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status.

  Breast cancer research : BCR 20070101

• [Targeting ErbB receptors in breast cancer].

  Bulletin du cancer 20070101

• [Angiogenesis targeting in breast cancer].

  Bulletin du cancer 20070101

• Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

  Breast cancer research : BCR 20070101

• Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy.

  Molecular systems biology 20070101

• Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.

  PloS one 20070101

• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  The New England journal of medicine 20061228

• Targeted therapy for metastatic breast cancer.

  The New England journal of medicine 20061228

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20061201

• Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.

  Clinical genitourinary cancer 20061201

• The molecular biology and immunology of glioblastoma multiforme (GBM) with the presentation of an immunotherapy protocol for a clinical trial.

  Acta microbiologica et immunologica Hungarica 20061201

• Lapatinib - overview and current role in metastatic breast cancer.

  Cancer research and treatment : official journal of Korean Cancer Association 20061201

• Closing in on a cure.

  U.S. news & world report 20061023

• Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.

  Biochemical pharmacology 20061016

• [Molecular diagnostic and targeted therapy--'Barking dogs are going to bite': presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006].

  Zentralblatt fur Gynakologie 20061001

• Delivery of a healthy baby after first-trimester maternal exposure to lapatinib.

  Clinical breast cancer 20061001

• Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

  British journal of cancer 20060918

• Three new drugs available to fight kidney cancer.

  Journal of the National Cancer Institute 20060906

• Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.

  Bioorganic & medicinal chemistry letters 20060901

• Emerging drugs to replace current leaders in first-line therapy for breast cancer.

  Expert opinion on emerging drugs 20060901

• Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.

  Anti-cancer drugs 20060901

• Two targets, one drug for new EGFR inhibitors.

  Journal of the National Cancer Institute 20060816

• New hope for RCC patients.

  European journal of cancer (Oxford, England : 1990) 20060801

• Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060715

• Trials probe new agents for kidney cancer.

  JAMA 20060712

• HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.

  Cancer cell 20060701

• Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer.

  Drugs of today (Barcelona, Spain : 1998) 20060701

• Systemic therapy in the palliative management of advanced salivary gland cancers.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060610

• Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.

  Critical reviews in oncology/hematology 20060601

• Canonical WNT signaling pathway and human AREG.

  International journal of molecular medicine 20060601

• [Molecular-targeted agents in breast cancer].

  Gan to kagaku ryoho. Cancer & chemotherapy 20060601

• A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.

  British journal of cancer 20060522

• Alkynyl pyrimidines as dual EGFR/ErbB2 kinase inhibitors.

  Bioorganic & medicinal chemistry letters 20060501

• Her-2 targeted therapy: beyond breast cancer and trastuzumab.

  Current oncology reports 20060301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060301

• Determination of lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS).

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.

  The Annals of pharmacotherapy 20060201

• Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

  Cancer research 20060201

• Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

  Cancer research 20060201

• Adjuvant trastuzumab: progress, controversies, and the steps ahead.

  Current oncology (Toronto, Ont.) 20060201

• Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.

  British journal of cancer 20060116

• Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

  Cancer research 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• Lessons from the drug discovery of lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor.

  Current topics in medicinal chemistry 20060101

• HER2 therapy: molecular mechanisms of trastuzumab resistance.

  Breast cancer research : BCR 20060101

• Lapatinib: current status and future directions in breast cancer.

  The oncologist 20060101

• A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma.

  BMC cancer 20060101

• Dual/pan-HER tyrosine kinase inhibitors: focus in breast cancer.

  Advances in experimental medicine and biology 20060101

• Targeting the EGFR pathway for cancer therapy.

  Current medicinal chemistry 20060101

• [Her-2/neu analysis--new data?].

  Verhandlungen der Deutschen Gesellschaft fur Pathologie 20060101

• Role of tyrosine kinase inhibitors in cancer therapy.

  The Journal of pharmacology and experimental therapeutics 20051201

• GlaxoSmithKline cancer drug threatens Herceptin market.

  Nature biotechnology 20051201

• Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.

  Clinical breast cancer 20051201

• Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

  Oncology (Williston Park, N.Y.) 20051101

• Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.

  Oncogene 20050915

• Antitumor activity of HER-2 inhibitors.

  Cancer letters 20050908

• Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050810

• Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.

  Endocrine-related cancer 20050701

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Small molecules with EGFR-TK inhibitor activity.

  Current drug targets 20050501

• Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.

  Cancer research 20050415

• Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050410

• A small molecule-kinase interaction map for clinical kinase inhibitors.

  Nature biotechnology 20050301

• EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head.

  PLoS medicine 20050301

• Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.

  PLoS medicine 20050301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050301

• The epidermal growth factor receptor as a target for colorectal cancer therapy.

  Seminars in oncology 20050201

• Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects.

  Investigational new drugs 20050101

• The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.

  Cancer research 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050101

• Therapeutic targeting of multiple signaling pathways in malignant pleural mesothelioma.

  Oncology 20050101

• Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.

  Breast cancer research : BCR 20050101

• Lapatinib: the evidence for its therapeutic value in metastatic breast cancer.

  Core evidence 20050101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20041101

• A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

  Cancer research 20040915

• Early success of combined EGFR and Her2 receptor blockade as a clinical strategy in breast cancer.

  Cancer biology & therapy 20040601

• Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.

  International journal of radiation oncology, biology, physics 20040201

• Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

  Oncogene 20040122

• Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.

  Bioorganic & medicinal chemistry letters 20040105

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040101

• Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib.

  The oncologist 20040101

• Targeting HER2 in brain metastases from breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031115

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031001

• Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.

  Lung cancer (Amsterdam, Netherlands) 20030801

• Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

  Bioorganic & medicinal chemistry letters 20030224

• Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways.

  Oncogene 20020912

• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  Molecular cancer therapeutics 20011201